Compare TTWO & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TTWO | ONC |
|---|---|---|
| Founded | 1993 | 2010 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.2B | 34.8B |
| IPO Year | 1999 | N/A |
| Metric | TTWO | ONC |
|---|---|---|
| Price | $215.25 | $298.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 17 | 10 |
| Target Price | $283.35 | ★ $386.70 |
| AVG Volume (30 Days) | ★ 2.7M | 240.2K |
| Earning Date | 05-04-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,633,600,000.00 | N/A |
| Revenue This Year | $20.49 | $770.07 |
| Revenue Next Year | $36.48 | $15.48 |
| P/E Ratio | ★ N/A | $614.06 |
| Revenue Growth | ★ 5.31 | N/A |
| 52 Week Low | $188.56 | $196.53 |
| 52 Week High | $264.79 | $385.22 |
| Indicator | TTWO | ONC |
|---|---|---|
| Relative Strength Index (RSI) | 51.68 | 29.71 |
| Support Level | $188.65 | $234.09 |
| Resistance Level | $240.42 | $306.61 |
| Average True Range (ATR) | 7.44 | 10.29 |
| MACD | 3.57 | -7.64 |
| Stochastic Oscillator | 82.67 | 6.09 |
Take-Two is one of the largest global developers and publishers of video games, with labels including Rockstar, 2K, and Zynga. Grand Theft Auto is the firm's biggest franchise, accounting for about 30% of total sales for the past decade. NBA 2K is the industry's dominant basketball video game, with Take-Two releasing a new version annually. Other notable franchises include Red Dead Redemption, Borderlands, and Civilization. Typically, more than three-fourths of the firm's sales are from in-game spending, with the remainder coming from initial game sales. Since acquiring Zynga in 2022, mobile makes up about half of total sales.
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue.